Date: 2013-02-20
Type of information: R&D agreement
Compound: new small molecule anti-cancer drugs for defined therapeutic targets
Company: 4SC Discovery (Germany) BioNTech (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
services
Action mechanism:
Disease:
Details: 4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, has announced that its wholly owned research subsidiary 4SC Discovery GmbH has entered into an extensive research partnership in the field of cancer medicine with biopharmaceutical company BioNTech AG. This spin-off of Johannes Gutenberg-Universität Mainz researches and develops novel immune-based technologies to boost the body\'s immune system for the targeted treatment of numerous cancers.
In this service partnership, which has commenced at the beginning of the year and will run for three years, 4SC Discovery will be commissioned by BioNTech to identify new small molecule anti-cancer drugs for defined therapeutic targets and optimise these for BioNTech. BioNTech is planning to conduct preclinical testing and, if successful, bring the compounds to the clinical development stage. As part of this collaboration, the two partners are already working on four cancer therapy projects at various stages of early-phase pharmaceutical research. This is the second strategic partnership forged by the two companies. In December 2012, 4SC Discovery and BioNTech concluded a license agreement for 4SC Discovery\'s TLR agonists for use in cancer immunotherapy.
Financial terms: Under the partnership, BioNTech will pay 4SC Discovery a cost-based service fee as well as success-based payments on achievement of specific development or sales milestones plus royalties linked to future net sales of the products.
Latest news:
